Work

Zanzalintinib plus atezolizumab is first immunotherapy regimen to benefit patients with metastatic CRC

Year: 2026

Type: article

Source: Cancer

DOI: 10.1002/cncr.70235

Author: Leah Lawrence

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7127674567

FWCI:

Cites:

Cited by:

Related to: